SeaBeLife secures €1.2m in funding
Biotech company, specialising in cell necrosis prevention, has announced a successful funding round, securing €1.2m in additional seed funding.
ADVERTISEMENT
About Margarita Milidakis
This author has not written his bio yet.
But we are proud to say that Margarita Milidakis contributed 42 entries already.
Entries by Margarita Milidakis
Crucible Therapeutics spins out with £5m
University of Sheffield spinout gets £5m for gene therapies targeting ALS and FTD, advancing towards clinical trials.
Oxford Biomedica acquires ABL Europe for €15m
Oxford Biomedica’s proposed acquisition of ABL Europe from Institut Mérieux, at a consideration of €15m propels global leadership in cell and gene therapy.
Connect in Pharma 2023 revealed latest trends in pharmaceutical manufacturing and drug delivery
Hosting leading industry experts from across Europe, Connect in Pharma 2023 revealed future trends in pharma and AI, sustainability, and preventative medicine during a two-day meeting in Geneva on 14 & 15 June.
Fresh money for Carbios
Carbios SAS has announced a capital increase of around €122m that may grow up to €141m.
Smarter, faster, cheaper: Veeva shows how
This year’s Veeva R&D and Quality Summit in Madrid, accentuated the current trends and needs of the pharma and life sciences industries.
The innovative power of the chemical industry assembled
The Chemspec Europe 2023 provided insights into current challenges of the chemical industry, as well as the solutions it holds.
VectivBio taken over in $1bn acquisition
GI specialist Ironwood Pharmaceuticals Inc. has announced to acquire Swiss VectivBio Holding AG for $17 per share in an all-cash transaction.
Upscaling AAV gene therapy
Biovian Oy’s second generation AAV platform will include Remedium Bio Inc.’s lead treatment candidate against Osteoarthritis.
Neurodegenerative disorders are being fought with €28m
Danish Teitur Trophics ApS announced the completion of a €28m Series A funding to progress drugs against several neurodegenerative diseases.